Albiglutide (FDA Application Pending) Has Greater Tolerability, Comparable A1c Reductions, But Less Weight Loss

Research showed type 2 diabetes patients who took once-weekly albiglutide attained significant reductions in A1C, comparable with those who were on once-daily liraglutide. "The data indicate that albiglutide is a reasonable alternative to other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes. Researchers said that, "It has good efficacy and a better tolerability profile with less nausea." But liraglutide had greater weight loss (2.19 vs 0.64kg). Lancet Diabetes Endocrinol 2014